Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

NEW YORK, Feb. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

http://www.reportlinker.com/p0795162/Global-Pharmaceutical-Survey-2013-2014---Market-Trends-Buyer-Spend-and-Procurement-Strategies-in-the-Global-Pharmaceutical-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Product Synopsis
"Global Pharmaceutical Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" is a new report by ICD Research that analyzes how pharmaceutical industry companies' procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report gives access to category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities, as well as access to information categorized by region, company type, and size.

Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviours, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stakeholders in the value-chain of the global pharmaceutical industry.

What is the current market landscape and what is changing?
Executives from the global pharmaceutical industry anticipate an increase in levels of consolidation, with 61% of respondents projecting an increase in MandA activities in 2013.

What are the key drivers behind recent market changes?
The need for new product pipelines, new product acquisition, patent expiries, cost containment and credit availability have prompted companies to consolidate positions and look for merger and MandA acquisition.

What makes this report unique and essential to read?
This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical industry executives. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable).

Key Features and Benefits
Project industry trends and revenue growth expectations in 2013, and understand business confidence to make informed business decisions.

Drive revenues by understanding future product investment areas and key growth regions.

Uncover key challenges and opportunities, and identify the key actions required to maintain and win buyer business.

Formulate effective sales and marketing strategies by identifying how buyer budgets are changing and the direction of spending in the future. Better promote your business by aligning your capabilities and business practices with your customer's changing needs

Secure stronger customer relationships by understanding the behaviour and changing strategies of industry buyers.

Key Market Issues
China, Brazil and India are the important emerging markets to offer growth in 2013.

'Market uncertainty', 'responding to price pressure', 'rising competition' and 'regulatory changes' are the leading business concerns for the global pharmaceutical industry in 2013.

Overall, for 2013, the average size of the annual procurement budget for global pharmaceutical industry buyer respondents is projected at US$127 million, against US$127 million in 2012 and US$110 million in 2011.

'Price', 'level of service' and 'existing relationship with supplier' are considered the most important factors for supplier selection in the global pharmaceutical industry, while 'environmental records and CSR', 'brand reputation' and 'proximity of supplier operations' are considered the least important.

While 16% of buyer respondents from the global pharmaceutical industry are willing to implement e-procurement in 2013 or beyond, 32% are already in the different stages of implementation ('partially implemented', 'completely implemented', and 'evaluation or pilot use')

Key Highlights
An analysis of revenue growth expectations by senior level respondents reveals that 62% are 'more optimistic' about their company's revenue growth in 2013.

A significant percentage of pharmaceutical manufacturing industry respondents highlighted that capital expenditure towards 'new product development', 'employee training', and 'IT infrastructure development' would increase in 2013.

The top three priorities for global pharmaceutical industry buyer respondents in 2013 are 'new products and services', 'improve operational efficiency' and 'expand in current markets'.

A total of 49% of respondents from pharmaceutical manufacturing companies, 68% of respondents from CROs and CMOs companies, and 64% of respondents from pharmaceutical industry supplier companies anticipate an increase of their current workforce in 2013.

Survey results show that respondents from the global pharmaceutical industry identified the US to offer the highest growth potential among developed countries in 2013-2014.

Table of Contents

1 Introduction
1.1 What is This Report About?
1.2 Definitions
1.3 Methodology
1.4 Profile of Survey Respondents: Global Pharmaceutical Industry
1.4.1 Global pharmaceutical industry: profile of buyer respondents
1.4.2 Global pharmaceutical industry: profile of supplier respondents
2 Executive Summary
3 Global Pharmaceutical Industry Dynamics
3.1 Revenue Growth Projections in the Global Pharmaceutical Industry
3.1.1 Revenue growth projections by company type
3.1.2 Revenue growth projections by region
3.1.3 Revenue growth projections by company turnover
3.1.4 Global pharmaceutical industry: revenue growth expectations by senior level respondents
3.2 Future Developments in Business Structure in the Global Pharmaceutical Industry
3.2.1 Future developments in business structure by buyers
3.2.2 Future developments in business structure by suppliers
3.2.3 Future developments in business structure by region
3.2.4 Future developments in business structure by company turnover
3.2.5 Future developments in business structure by senior level respondents
3.3 Change in Leading Company Strategies in the Global Pharmaceutical Industry
3.3.1 Change in leading company strategies by buyers
3.3.2 Change in leading company strategies by suppliers
3.3.3 Change in leading company strategies by region
3.3.4 Change in leading company strategies by company turnover
3.4 Merger and Acquisition (MandA) Activity Projections in the Global Pharmaceutical Industry
3.4.1 MandA activity projections by buyers
3.4.2 MandA activity projections by suppliers
3.4.3 MandA activity projections by region
3.4.4 MandA activity projections by company turnover
3.4.5 MandA activity projections by purchasing decision authority
3.4.6 Global pharmaceutical industry - expand abroad Vs MandA activity projections
3.5 Estimation of Capital Expenditure in the Global Pharmaceutical Industry
3.5.1 Estimation of capital expenditure by buyers
3.5.2 Estimation of capital expenditure by suppliers
3.5.3 Estimation of capital expenditure by region
3.5.4 Estimation of capital expenditure by company turnover
3.6 Planned Change in Staff Recruitment Activity in the Global Pharmaceutical Industry
3.6.1 Planned change in staff recruitment activity by buyers
3.6.2 Planned change in staff recruitment activity by suppliers
3.6.3 Planned change in staff recruitment activity by region
3.6.4 Planned change in staff recruitment activity by company turnover
4 Global Pharmaceutical Industry Market Growth Outlook
4.1 Global Pharmaceutical Industry: Demand in Emerging Markets
4.1.1 Demand in emerging markets by buyers
4.1.2 Demand in emerging markets by suppliers
4.1.3 Demand in emerging markets by region
4.1.4 Demand in emerging markets by company turnover
4.2 Global Pharmaceutical Industry - Growth Projections in Developed Countries
4.2.1 Growth projections in developed countries by buyers
4.2.2 Growth projections in developed countries by suppliers
4.2.3 Growth projections in developed countries by region
4.2.4 Growth projections in developed countries by company turnover
5 Threats and Opportunities for the Global Pharmaceutical Industry
5.1 Global Pharmaceutical Industry: Leading Business Concerns for 2013-2014
5.1.1 Leading business concerns for 2013-2014 by company type
5.1.2 Leading business concerns for 2013-2014 by region
5.1.3 Leading business concerns for 2013-2014 by company turnover
5.2 Global Pharmaceutical Industry: Key Supplier Actions to Maintain and Win Buyer Business
5.2.1 Actions to maintain and secure buyer business by buyers
5.2.2 Actions to maintain and secure buyer business by region
5.2.3 Actions to maintain and secure buyer business by company turnover
5.2.4 Actions to maintain and secure buyer business by purchasing decision authority
6 Global Pharmaceutical Industry Buyer Expenditure Activity
6.1 Annual Procurement Budgets in the Global Pharmaceutical Industry
6.1.1 Revenue growth vs. procurement budget
6.1.2 Annual procurement budgets by company type
6.1.3 Annual procurement budgets by region
6.1.4 Annual procurement budgets by company turnover
6.1.5 Annual procurement budgets by senior level respondents
6.2 Planned Change in Procurement Expenditure in the Global Pharmaceutical Industry
6.2.1 Planned change in procurement expenditure by buyer type
6.2.2 Planned change in procurement expenditure by region
6.2.3 Planned change in procurement expenditure by company turnover
6.2.4 Planned change in procurement expenditure vs. revenue growth optimism
6.2.5 Planned change in procurement expenditure vs. cost containment
6.3 Planned change in Procurement Expenditure by Product and Service Category
6.3.1 Planned change in procurement expenditure by product and service category - region
6.3.2 Planned change in procurement expenditure by product and service category - company turnover
6.4 Global Pharmaceutical Industry: Variations in Regional Supplier Prices
6.4.1 Variations in regional supplier prices by company type
6.4.2 Variations in regional supplier prices by region
6.4.3 Variations in regional supplier prices by company turnover
7 Global Pharmaceutical Industry: Procurement Behaviors and Strategies
7.1 Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection
7.2 E-procurement in the Global Pharmaceutical Industry
7.2.1 E-procurement in the global pharmaceutical industry by buyer type
7.2.2 E-procurement in the global pharmaceutical industry by region
7.2.3 E-procurement in the global pharmaceutical industry by company turnover
8 Appendix
8.1 Global Pharmaceutical Industry Survey Results- Closed Questions
8.2 Methodology
8.3 Contact us
8.4 About ICD Research
8.5 Disclaimer

List of Tables

Table 1: Global Pharmaceutical Industry Survey Respondents by Company Type, 2013
Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2013
Table 3: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2013
Table 4: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2013
Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2013
Table 6: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2013
Table 7: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2013
Table 8: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Table 9: Revenue Growth Optimism in the Global Pharmaceutical Industry by Buyers (%), 2010-2013
Table 10: Revenue Growth Optimism in the Global Pharmaceutical Industry by Suppliers (%), 2010-2013
Table 11: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%),2013
Table 12: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 13: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 14: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Table 15: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 16: Key Expected Changes in Business Structure by Turnover - Global Pharmaceutical Industry (%), 2013
Table 17: Key Expected Changes In Business Structure by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 18: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Table 19: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 20: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Table 21: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Table 22: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Table 23: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 24: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Table 25: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Table 26: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Table 27: Global Pharmaceutical Industry - Expand Abroad vs. MandA Activity Projections(%), 2013
Table 28: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Table 29: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Table 30: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Table 31: Global Pharmaceutical Industry - Increase in Capital Expenditure by Region (%), 2013
Table 32: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Table 33: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Table 34: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Table 35: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Table 36: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Table 37: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Table 38: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Table 39: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Table 40: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Table 41: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Table 42: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Turnover (%), 2013
Table 43: Global Pharmaceutical Industry - Leading Business Concerns (%), 2010-2013
Table 44: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Table 45: Global Pharmaceutical Industry - Leading Business Concerns by Region (%), 2013-2014
Table 46: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Table 47: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Table 48: Global Pharmaceutical Industry - Securing Buyer Business by Turnover (%), 2013
Table 49: Securing Buyer Business in the Global Pharmaceutical Industry - by Purchasing Decision Authority (%), 2013
Table 50: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Table 51: Global Pharmaceutical Industry Buyers - Increase in Revenue Growth vs. Procurement Budget (%), 2013
Table 52: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Table 53: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Region(%), 2013
Table 54: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Table 55: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Table 56: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Table 57: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Table 58: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Table 59: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Table 60: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Revenue Growth (%), 2013
Table 61: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Cost Containment (%), 2013
Table 62: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Table 63: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Table 64: Increase in Expenditure by Product and Service Category - Buyers by Region , 2013
Table 65: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Table 66: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Table 67: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Table 68: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Turnover (%), 2013
Table 69: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Table 70: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Table 71: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Table 72: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Table 73: E-Procurement in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 74: Survey Results - Closed Questions

List of Figures

Figure 1: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Figure 2: Revenue Growth Optimism in the Global Pharmaceutical Industry by Company Type (%), 2010-2013
Figure 3: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%), 2013
Figure 4: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Figure 5: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Figure 6: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 7: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 8: Key Expected Changes in Business Structure by Region - Global Pharmaceutical Industry (%), 2013
Figure 9: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 10: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 11: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Figure 12: Change in Leading Company Strategies by Turnover - Global Pharmaceutical Industry (%), 2013
Figure 13: MandA Activity Projections - Global Pharmaceutical Industry (%), 2013
Figure 14: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Figure 15: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Figure 16: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 17: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Figure 18: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Figure 19: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Figure 20: Global Pharmaceutical Industry - Expand Abroad Vs MandA Activity Projections (%), 2013
Figure 21: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Figure 22: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Figure 23: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Figure 24: Global Pharmaceutical Industry - Increase in Capital Expenditure by Turnover (%), 2013
Figure 25: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Figure 26: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Figure 27: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Figure 28: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Figure 29: Global Pharmaceutical Industry: Top Ten Growth Regions (%), 2013
Figure 30: Global Pharmaceutical Industry: Top Five Emerging Markets, 2013
Figure 31: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Figure 32: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Figure 33: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Figure 34: Global Pharmaceutical Industry - Demand in Emerging Markets by Region (%), 2013
Figure 35: Global Pharmaceutical Industry - Demand in Emerging Markets by Turnover (%), 2013
Figure 36: Global Pharmaceutical Industry - Top Five Developed Regions by Growth (%), 2013
Figure 37: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Figure 38: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Figure 39: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Figure 40: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Region (%), 2013
Figure 41: Global Pharmaceutical Industry - Top Five Leading Business Concerns, 2013
Figure 42: Global Pharmaceutical Industry - Leading Business Concerns (%), 2013
Figure 43: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Figure 44: Global Pharmaceutical Industry - Leading Business Concerns by Turnover (%), 2013-2014
Figure 45: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Figure 46: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Figure 47: Global Pharmaceutical Industry - Securing Buyer Business by Region (%), 2013
Figure 48: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Figure 49: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Figure 50: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Figure 51: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Figure 52: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Figure 53: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Figure 54: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Figure 55: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Figure 56: Future Change in Expenditure by Product and Service Category, Buyers , 2013
Figure 57: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Figure 58: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Figure 59: Increase in Expenditure by Product and Service Category - Buyers by Turnover (%), 2013
Figure 60: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Figure 61: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Figure 62: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Figure 63: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Figure 64: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Figure 65: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Figure 66: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Figure 67: E-Procurement in the Global Pharmaceutical Industry: by Turnover (%), 2013

Companies Mentioned

Eli Lilly , Avid Radiopharmaceuticals , Roche , Johnson and Johnson , Mozambica , Mozambican Medicines Company , Mylan Pharmaceuticals Private Limited , AstraZeneca , MedImmune , WuXi AppTec , Pfizer , Bristol-Myers , Sanofi , Astellas Pharma , Sanwa Kagaku Kenkyusho , STS Health , Avita Medical , Guppy Plastics , Mylan Laboratories , TiGenix , DiaMedica , Suzhou Pharma , Arrowhead Research , Shire , biOasis Technologies , UCB , Immunovative Therapies , Lonza , UBICHEM Group , UBICHEM Pharma , BASF , Equateq , SAFC , Sigma-Aldrich , Semantelli , Novartis , UMN Pharma , Catalent Pharma Solutions , Sihuan Pharmaceutical Holdings , Dendreon Corporation , DBV Technologies , GENEWIZ , Bayer HealthCare Pharmaceuticals , Vitapath , Nextrials , LGC , Quotient Bioresearch , Bio-Rad Laboratories , AbD Serotec , MorphoSys AG , NextWave Pharmaceuticals , OPKO Health , DiscoveRx , BioSeek , Poxel , Nuron Biotech , Takeda, Takeda America Holdings, LigoCyte Pharmaceuticals, Block Engineering, Lexmark International, Acuo Technologies, Zhejiang Hisun Pharmaceuticals, Abbot, Essex Woodlands, Novavax, CPL Biologicals, Dr. Reddy's Laboratories, Debiopharm Group, Omkar Speciality Chemicals, Thermo Fisher Scientific, Bosch Packaging Technology, Amgen, TG Therapeutics, Ildong Pharmaceutical, Teva Pharmaceutical Industries, Handok Pharmaceuticals, GE Healthcare Life Sciences, GE Healthcare, Kiadis Pharma, Aptuit, Aegerion Pharmaceuticals, Novasep, ATS Labs, Galapagos and Cangenix

To order this report:
Pharmaceutical Industry:
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
Software development, like manufacturing, is a craft that requires the application of creative approaches to solve problems given a wide range of constraints. However, while engineering design may be craftwork, the production of most designed objects relies on a standardized and automa...
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset po...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained throug...
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiat...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE